[October 04, 2016] |
|
OSE Immunotherapeutics to Present the Preclinical Data of Its New Checkpoint Inhibitor Effi-DEM on SIRP-a/CD47 Strategic Pathway at the 2016 Immune Checkpoint Inhibitors Conference
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE)
(Paris:OSE), a biotechnology company developing immunotherapies of
activation and regulation in immuno-oncology, auto-immune diseases and
transplantation, will present in an oral session preclinical studies
results for Effi-DEM, a new generation checkpoint inhibitor targeting
Myeloid Derived Suppressor Cells (MDSC) and Tumor Associated Macrophages
(TAM), at the ICI (Immune Checkpoint Inhibitors) conference (Munich,
November 16th to 18th, 2016).
Bernard Vanhove, Chief Operating Officer of OSE Immunotherapeutics, in
charge of R&D and International scientific collaborations, will present
and comment all of the data from its preclinical studies conducted with
Effi-DEM both in vivo and in vitro and in various cancer
models.
Effi-DEM, a new generation checkpoint inhibitor specifically targeting
the SIRP- a receptor on the strategic SIRP-a/CD47 pathway, has the
potential to transform suppressor myeloid and macrophage cells in
non-suppressive cells, thereby inducing a reactivation of the immune
response, an anti-tumor impact and an immune memory.
SIRP-a is a receptor strongly expressed by Myeloid Derived Suppressor
Cells (MDSC) and Tumor Associated Macrophages (TAM) and its ligand is
CD47. Suppressor immune cells MDSC and TAM play a key role in tumor
growth of inflammatory cancers.
Effi-DEM has shown to be effective in various aggressive cancer models
with encouraging preclinical results, both in monotherapy and in
therapeutic combinations with anti-PD-L1 (checkpoint inhibitors) and
anti-CD137 (4-1BB), activators of the T-cell response. Significant
efficacy and survival increase data were demonstrated in
hepatocarcinoma, melanoma and triple negative breast cancer models.
"These preclinical results validate the therapeutic potential of our
new generation checkpoint inhibitor Effi-DEM in immuno-oncology, and
show how the product enhances immune response by targeting novel
checkpoint SIRP-a/CD 47 pathway. OSE Immunotherapeutics is at the
forefront of this new immuno-oncology area and clearly focuses in
developing such an innovative product", commented Dominique
Costantini, Chief Executive Officer of OSE Immunotherapeutics.
Details of the presentation are as follows:
Title: Selective Targeting of The SIRP-a Immune Checkpoint To
Dampen Suppression By Myeloïd-Derived Suppressor Cells And Control
Polarization Of Human Macrophages
Date/Time: Thursday, November 17, 2016, 10:30am CET Location:
Maritim Hotel München, Goethestraße 7, 80336 Munich, Germany
These preclinical data will also be presented in an abstract at the
Annual World Gene Convention-2016 (WGC-2016), which will be held during
November 3-5, 2016 in Shanghai, China.
About ICI (IMMUNE CHECKPOINT INHIBITORS) EUROPE ICI Europe
is a forum dedicated to immune checkpoint inhibitors. It focuses
specifically on the preclinical, translational and clinical challenges
that drug developers face in advancing more checkpoint inhibitors onto
the market. Combining data driven case studies with interactive
experience sharing sessions, its program provides cutting edge insights
nto novel checkpoint pathways, more predictive preclinical models, the
optimal combination strategies, patient stratification biomarkers and
emerging clinical trial data.
ABOUT WGC (ANNUAL WORLD GENE CONVENTION) WGC-2016 features a
very strong technical program, mainly focused on breakthroughs in DNA
and RNA research, advances of genomics & genetics, the frontier research
of life sciences. It aims to provide a platform for all experts from
academia, industry and national labs to discuss latest hot researches
and achievements.
ABOUT OSE IMMUNOTHERAPEUTICS Our ambition is to become
a world leader in activation and regulation immunotherapies
OSE Immunotherapeutics is a biotechnology company led by world-class
immunologists and focused on the development of innovative
immunotherapies for immune activation and regulation in the fields of
immuno-oncology, auto-immune diseases and transplantation. The
company has a balanced portfolio of first-in-class products with a
diversified risk profile ranging from clinical phase 3 registration
trials to R&D:
-
Tedopi®, a combination of 10 optimized neo-epitopes to induce
specific T activation in immuno-oncology - currently in
registration Phase 3 trial advanced NSCLC HLA A2+ patients EU /US - Orphan
Status in the US - registration expected in 2019 - a Phase 2 with
Tedopi® in combination with a checkpoint inhibitor in NSCLC is
considered in 2017 - the product is also considered in other cancer
indications.
-
FR104, CD28-antagonist in immunotherapy - Phase 1 trial
completed - targets autoimmune diseases and transplantation
- licensed to J&J to pursue clinical development
-
Effi-7, interleukin receptor 7 antagonist - in preclinical
development for inflammatory bowel diseases and other
autoimmune diseases
-
Effi-DEM, new generation checkpoint inhibitor targeting the SIRP-a
receptor on the strategic SIRP-a/CD47 pathway - in preclinical
development for immuno-oncology
-
R&D: candidates targeting new receptors in immuno-oncology
The portfolio's blockbuster potential gives OSE Immunotherapeutics the
ability to enter into global agreements at different stages of
development with major pharmaceutical players, such as the one signed
for FR104 with the J&J Group.
Immunotherapy is a highly promising and growing market. By 2023
Immunotherapy of cancer could represent nearly 60% of treatments against
less than 3% at present * and the projected market is estimated at $67
billion in 2018 **.
There are more than 80 autoimmune diseases that represent a significant
market including major players in the pharmaceutical industry with sales
upper $10 billion for the main products. The medical need is largely
unmet and requires the provision of new innovative products involved in
the regulation of the immune system.
*Citi Research Equity **BCC (News - Alert) Research
More information: http://ose-immuno.com
Click and follow us on Twitter
and Linkedln
Forward-looking statements This press release
contains express or implied information and statements that might be
deemed forward-looking information and statements in respect of OSE
Immunotherapeutics. They do not constitute historical facts. These
information and statements include financial projections that are based
upon certain assumptions and assessments made by OSE Immunotherapeutics'
management in light of its experience and its perception of historical
trends, current economic and industry conditions, expected future
developments and other factors they believe to be appropriate. These
forward-looking statements include statements typically using
conditional and containing verbs such as "expect", "anticipate",
"believe", "target", "plan", or "estimate", their declensions and
conjugations and words of similar import. Although the OSE
Immunotherapeutics management believes that the forward-looking
statements and information are reasonable, the OSE Immunotherapeutics'
shareholders and other investors are cautioned that the completion of
such expectations is by nature subject to various risks, known or not,
and uncertainties which are difficult to predict and generally beyond
the control of OSE Immunotherapeutics. These risks could cause actual
results and developments to differ materially from those expressed in or
implied or projected by the forward-looking statements. These risks
include those discussed or identified in the public filings made by OSE
Immunotherapeutics with the AMF. Such forward-looking statements are not
guarantees of future performance. This press release includes only
summary information and should be read with the OSE Immunotherapeutics
Reference Document filed with the AMF on 8 June 2016 under the number
R.16-052, the consolidated financial statements and the management
report for the fiscal year 2015, as well as the Merger Document
registered with the AMF on 26 April 2016 under number E.16-026, all
available on the OSE Immunotherapeutics' website. Other than as
required by applicable law, OSE Immunotherapeutics issues this press
release at the date hereof and does not undertake any obligation to
update or revise the forward-looking information or statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161004006171/en/
[ Back To TMCnet.com's Homepage ]
|